MA50353A - Anticorps ciblant pdl1 et procédés d'utilisation associés - Google Patents

Anticorps ciblant pdl1 et procédés d'utilisation associés

Info

Publication number
MA50353A
MA50353A MA050353A MA50353A MA50353A MA 50353 A MA50353 A MA 50353A MA 050353 A MA050353 A MA 050353A MA 50353 A MA50353 A MA 50353A MA 50353 A MA50353 A MA 50353A
Authority
MA
Morocco
Prior art keywords
pdl1
associated methods
targeting antibodies
targeting
antibodies
Prior art date
Application number
MA050353A
Other languages
English (en)
Inventor
Matthias Brock
Tea Gunde
Christian Hess
Alexandre Simonin
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP17195781.4A external-priority patent/EP3470429A1/fr
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Publication of MA50353A publication Critical patent/MA50353A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Liquid Crystal Substances (AREA)
MA050353A 2017-10-10 2018-10-09 Anticorps ciblant pdl1 et procédés d'utilisation associés MA50353A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17195781.4A EP3470429A1 (fr) 2017-10-10 2017-10-10 Anticorps dirigés contre pdl1 et leurs procédés d'utilisation
EP18167094 2018-04-12
EP18180816 2018-06-29

Publications (1)

Publication Number Publication Date
MA50353A true MA50353A (fr) 2020-08-19

Family

ID=63834022

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050353A MA50353A (fr) 2017-10-10 2018-10-09 Anticorps ciblant pdl1 et procédés d'utilisation associés

Country Status (11)

Country Link
US (2) US12077588B2 (fr)
EP (1) EP3694879A1 (fr)
JP (3) JP7791650B2 (fr)
KR (2) KR20200063147A (fr)
CN (2) CN111225926B (fr)
AU (2) AU2018348430B2 (fr)
CA (1) CA3074802A1 (fr)
IL (2) IL273578B1 (fr)
MA (1) MA50353A (fr)
SG (1) SG11202001654TA (fr)
WO (1) WO2019072869A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7130678B2 (ja) * 2017-06-05 2022-09-05 ヌマブ セラピューティクス アクチェンゲゼルシャフト 新規抗ｈｓａ抗体
PE20200849A1 (es) * 2017-10-10 2020-08-20 Numab Therapeutics AG Anticuerpo multiespecifico
KR20210070323A (ko) * 2019-04-26 2021-06-14 아이-맵 바이오파마 유에스 리미티드 인간 pd-l1 항체
EP3816185A1 (fr) * 2019-11-04 2021-05-05 Numab Therapeutics AG Anticorps multi-spécifique contra pd-l1 et antigène associé à une tumeur
JP2026504180A (ja) 2023-01-30 2026-02-03 カイマブ・リミテッド 抗体
CN121532211A (zh) * 2023-05-19 2026-02-13 努玛治疗有限公司 具有降低的免疫原性的抗体可变结构域及抗体
WO2025133389A1 (fr) 2023-12-22 2025-06-26 Numab Therapeutics AG Domaines de liaison à un anticorps ayant une spécificité pour lilrb2

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP1291360A1 (fr) 1991-12-13 2003-03-12 Xoma Corporation Procedes et matieres de preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
WO1998056915A2 (fr) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Polypeptides d'anticorps artificiels
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
CN1753912B (zh) * 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
PT2504364T (pt) 2009-11-24 2017-11-14 Medimmune Ltd Agentes de ligação direcionados contra b7-h1
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
EP2994490A1 (fr) * 2013-05-10 2016-03-16 Numab AG Constructions bispécifiques et leur utilisation dans le traitement de plusieurs maladies
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
MX395604B (es) 2015-06-15 2025-03-25 Numab Therapeutics AG Formato de anticuerpo multiespecífico heterodimérico.
CN106939047B (zh) 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
MX2018008308A (es) * 2016-01-11 2019-05-15 Inhibrx Inc Proteinas de fusion de union a 41bb multivalentes y multiespecificas.
US11129047B2 (en) * 2017-05-05 2021-09-21 Nokia Technologies Oy Radio link control status reporting

Also Published As

Publication number Publication date
US20200283528A1 (en) 2020-09-10
CN111225926B (zh) 2025-03-14
IL323510A (en) 2025-11-01
SG11202001654TA (en) 2020-03-30
CA3074802A1 (fr) 2019-04-18
IL273578A (en) 2020-05-31
JP2023166403A (ja) 2023-11-21
AU2018348430A1 (en) 2020-03-12
CN120248120A (zh) 2025-07-04
KR20250057935A (ko) 2025-04-29
IL273578B1 (en) 2025-11-01
AU2018348430B2 (en) 2025-09-04
JP7791650B2 (ja) 2025-12-24
JP2025102791A (ja) 2025-07-08
WO2019072869A1 (fr) 2019-04-18
JP7649825B2 (ja) 2025-03-21
JP2021501569A (ja) 2021-01-21
US12077588B2 (en) 2024-09-03
KR20200063147A (ko) 2020-06-04
CN111225926A (zh) 2020-06-02
US20250066482A1 (en) 2025-02-27
AU2025271488A1 (en) 2026-01-08
EP3694879A1 (fr) 2020-08-19

Similar Documents

Publication Publication Date Title
FR24C1050I1 (fr) Récepteurs d'antigènes chimériques basés sur des anticorps à domaine unique et leurs méthodes d'utilisation
MA50956A (fr) Anticorps anti-cd137 et procédés d'utilisation correspondants
MA50359A (fr) Anticorps anti-cd38 et procédés d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
FR24C1044I2 (fr) Anticorps anti-c5 et leurs procédés d'utilisation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
MA50957A (fr) Anticorps anti-tigit et leurs méthodes d'utilisation
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
EP3797123A4 (fr) Anticorps anti-ox40 et procédés d'utilisation
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA45123A (fr) Anticorps anti-tim-3 et leurs méthodes d'utilisation
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
EP3436476A4 (fr) Anticorps anti-ryk et leurs procédés d'utilisation
EP3472200A4 (fr) Anticorps anti-myostatine et leurs procédés d'utilisation
EP3383913A4 (fr) Anticorps ciblant la protéine de type récepteur fc 5 et procédés d'utilisation
EP3710589A4 (fr) Anticorps anti-c1s et procédés d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA50353A (fr) Anticorps ciblant pdl1 et procédés d'utilisation associés
MA45671A (fr) Anticorps antivirus zika et procédés d'utilisation
EP3731867A4 (fr) Anticorps anti-lrp5/6 et leurs procédés d'utilisation
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA51552A (fr) Anticorps anti-ox40 et procédés d'utilisation
EP3472316A4 (fr) Anticorps anti-c5 et leurs procédés d'utilisation
EP3525583A4 (fr) Anticorps anti-c1s et leurs méthodes d'utilisation